Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma is a research paper published in Cancer Cell (2023). On theSindex it has a DataRank of 0. It has been cited 80 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: P01 CA167575
National Institutes of Health
Grant: R01 CA 227505-03
National Institutes of Health
Grant: R01 CA 243486-02
National Institutes of Health
Grant: R01 CA 244936-02
National Institutes of Health
Grant: R01 CA 231295-03
National Institutes of Health
Grant: R35 CA197633
National Cancer Institute
Grant: P30 CA008748
National Institutes of Health
Grant: 1R01CA231295-01
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
National Institutes of Health
Grant: 5R01CA244936-03
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
National Institutes of Health
Grant: 2R35CA197633-08
Next Generation Cancer Immunotherapies to Defeat Melanoma
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5R01CA227505-04
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
FWCI
9.48
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords